TScan Therapeutics (NASDAQ:TCRX) Given New $7.00 Price Target at HC Wainwright

TScan Therapeutics (NASDAQ:TCRX) had its target price lowered by HC Wainwright from $10.00 to $7.00 in a report released on Thursday,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities research analysts have also recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of TScan Therapeutics in a report on Wednesday, October 8th. Wedbush reiterated an “outperform” rating and set a $7.00 target price on shares of TScan Therapeutics in a research report on Tuesday, August 12th. Needham & Company LLC dropped their price target on TScan Therapeutics from $9.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, November 4th. Finally, BTIG Research downgraded TScan Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 4th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $6.60.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $1.13 on Thursday. The firm’s fifty day simple moving average is $1.85 and its 200-day simple moving average is $1.70. The company has a quick ratio of 7.06, a current ratio of 7.06 and a debt-to-equity ratio of 0.18. The stock has a market cap of $64.13 million, a PE ratio of -1.01 and a beta of 1.00. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $5.30.

TScan Therapeutics (NASDAQ:TCRX) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.07. TScan Therapeutics had a negative net margin of 1,692.96% and a negative return on equity of 67.61%. The firm had revenue of $2.51 million during the quarter, compared to analysts’ expectations of $1.98 million. Analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Trading of TScan Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd acquired a new position in TScan Therapeutics in the 2nd quarter valued at about $26,000. Vanguard Personalized Indexing Management LLC purchased a new stake in shares of TScan Therapeutics during the second quarter worth about $29,000. Quadrature Capital Ltd purchased a new stake in shares of TScan Therapeutics during the second quarter worth about $33,000. Boothbay Fund Management LLC raised its position in shares of TScan Therapeutics by 50.0% in the second quarter. Boothbay Fund Management LLC now owns 24,363 shares of the company’s stock valued at $35,000 after buying an additional 8,121 shares during the last quarter. Finally, Hsbc Holdings PLC purchased a new position in shares of TScan Therapeutics during the first quarter valued at approximately $49,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.